ImmunityBio, Inc. cotiza a 9.99 USD y tiene una capitalización bursátil de $10.6B. En los últimos 12 meses ha facturado $166M con un margen de flujo de caja libre del -272.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product ca…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.22 | $-0.08 | $-0.06 |
| Estimado | $-0.05 | $-0.08 | $-0.07 | $-0.10 |
| Sorpresa | — | -175.0% | -14.3% | +40.0% |
| Métrica | IBRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 99.3% | 57.0% | +42.3% |
| Operating Margin | -226.0% | -38.6% | -187.4% |
| Net Margin | -310.2% | -33.6% | -276.6% |
| FCF Margin | -272.6% | -13.9% | -258.7% |
| ROE | — | -40.4% | — |
| ROA | -70.0% | -32.0% | -38.0% |
| Current Ratio | 5.10 | 2.84 | +2.26 |
| Debt / Equity | — | 0.28 | — |